Donanemab
Neurocognitive Disorders
Eli Lilly and Companymonoclonal_antibodyPhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 95/ 100
Competitive context
4 Active assets in the Neurocognitive Disorders cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
DEXAMETHASONE Eli Lilly and Company | Phase 3 | B |
Rotigotine I.R.C.C.S. Fondazione Santa Lucia | Phase 2 | B |
NA 831 Biomed Industries, Inc. | Phase 2 | B |
Tolcapone Sheppard Pratt Health System | Phase 2 | CCC |
Intranasal Auto-M2-Bfs Russian Academy of Medical Sciences | Phase 1/2 | CCC |
View all 9 →
Same molecule, other indications
Donanemab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →